## **VET 433A Immunosuppressive Drugs**

Drug	MOA	Indication	Adverse Effects	Dosing
Glucocorticoids	Inhibits phospholipase A2 and thus	First line of defense for	PU/PD, polyphagia	Starting dose
*Prednisone/Prednisolone	arachidonic acid release decreasing the	most auto-immune	Panting	prednisone 2 mg/kg/d
*Dexamethasone SP	production of prostaglandins and	<mark>diseases</mark>	Muscle wasting, weakness	
	thromboxane		Hepatomegaly,	Max dose of 60mg
	Decreased production of leukotrienes through		splenomegaly	total/day
	the lipoxygenase pathway		Calcinosis cutis	
			Hypercoagulability	Never use with
	Suppress cytokine production		GI ulceration with anemia	NSAIDS!
	Decreased antibody response		Alopecia, thin skin,	
	Reduced T-cell activation		impaired hair growth	
	Decreased phagocytosis			
	Decreased inflammatory cell influx		*Signs are similar to CS	
	Decreased Fc receptor expression by		of Cushing's disease*	
	macrophages			
	Lymphopenia, eosinophilia			
Cyclosporine	Calcineurin inhibitor	T-cell mediated auto-	GI signs	Atopica = veterinary
		immune diseases	Gingival hyperplasia	product
	Interacts with cytosolic protein, cyophilin, in		Hepatotoxicity	
	lymphocytes (T-lymphocytes) which blocks	Atopic dermatitis (derm)	Opportunistic infections	5mg/kg q 12h for
	transcription factors for interleukin 2 leading	5mg/kg q 24h until		immunosuppression
	to a down-regulation of T cell proliferation	clinical improvement 1-	<u>Drug interactions</u>	
	and activation	2 months then taper to q	P450 enzyme substrate,	Can start higher at
		48h then q 72h	concentration increased	10mg/kg but will need
			by azole antifungals,	to lower!
			macrolides,	
			fluoroquinolones, and	Need to monitor
			omeprazole	clinical response, IL-2
				expression, and trough
			May also inhibit MDR1	concentrations
			transporter (predispose to	
			ivermectin toxicity)	

## **VET 433A Immunosuppressive Drugs**

A (3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1		TT 11 ' 1' '	T 1 1 .	D 1 1 (C
Azathioprine	Thiopurine competes with adenine (purine	Usually in combination	Inexpensive drug but	Delayed onset of
	analog) leading to impaired nucleic acid	with glucocorticoids as	monitoring costs can add	action
	synthesis. This results in faulty transcription	a second-line agent	up \$\$\$	1 2 / 1 2 41 6
	and targets rapidly dividing cells (T and B			1-2 mg/kg 1 24h po for
	cells) along with the intestinal epithelium.		GI upset	7-14 days (loading
			Bone marrow suppression	dose)
			Hepatotoxicity	
			Impaired hair growth	Then DECREASE to
			Pancreatitis	0.5-1 mg/kg q 48h for
			Profound muscle	long term use
			weakness and tetraparesis	
			CELIEDE 1 CC	
			SEVERE adverse effects	
			in cats (bone marrow	
7.5	7.1.1.	71 11 2	suppression!)	
Mycophenolate mofetil	Inhibits purine synthesis	First-line for	GI toxicity	5-10 mg/kg q 12h
	Targets rapidly dividing cells (lymphocytes)	glomerulonephritis		
		G 111	Dose-dependent diarrhea	
		Second-line agent for		
		other autoimmune		
Y (2)	Y 1 11 12 2 1 1 1 1 1 1 1 1 1	diseases	CT	D 2.4 /1
Leflunomide	Inhibits pyrimidine synthesis	<u>IMPA</u>	GI toxicity	Dogs: 3-4 mg/kg po
	Targets rapidly dividing cells (lymphocytes)		<i>P</i>	sid
	Inhibits autoimmune T-cell proliferation and	Occasional utilized for	Bone marrow .	
CII I II	autoantibody production by B cells	other refractory disease	suppression/anemia	Cats: 2-3 mg/kg po sid
Chlorambucil	Alkylating agent (Leukeran)	Used most often in cats	Uncommon due to its low	2mg eod to every 3 <sup>rd</sup>
		IBD vs GI lymphoma	potency	day
			CI.	
			GI issues	
			Bone marrow suppression	